Pharmacokinetics and Pharmacodynamics of Oltipraz as a Chemopreventive Agent

Elora Gupta, Olufunmilayo I. Olopade, Mark J. Ratain, Rosemarie Mick, Theresa M. Baker, Frances K. Berezin, Al B Benson III, M. Eileen Dolan

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Oral oltipraz, as a single-dose treatment, was evaluated as a chemopreventive agent in 31 normal subjects. In a subset of subjects, the relationship between plasma oltipraz concentrations and the induction of lymphocyte glutathione (GSH) and glutathione S-transferase (GST) enzyme levels was evaluated. Pharmacokinetic analysis revealed nonlinear disposition of oltipraz with disproportionate 40-fold increase and 9.5-fold decrease in peak plasma concentrations (Cmax) and p.o. clearance, respectively, over the dose range of 100-500 mg. There was no correlation between the oltipraz dose and the absorption rate or the time to reach Cmax. Since oltipraz undergoes extensive metabolism, saturable first-pass elimination could be one of the sources of nonlinearity. Pharmacodynamic evaluation was conducted based on the percentage of elevation of GSH and GST levels over baseline in lymphocytes of subjects receiving 100 mg and 125 mg oltipraz. Induction was observed in both dose groups with a time lag between the maximum concentrations of oltipraz and that of GSH or GST. We also observed a linear correlation between oltipraz Cmax and the corresponding GSH and GST elevations. Subjects with higher Cmax values showed a greater increase over baseline in the GSH and GST levels. Mild toxicities were observed at all dose levels. The most common were flatulence, hunger, fatigue, and headache. These preliminary results indicate that oltipraz may be effective in inducing GSH and GST, an enzyme capable of carcinogen elimination.

Original languageEnglish (US)
Pages (from-to)1133-1138
Number of pages6
JournalClinical Cancer Research
Volume1
Issue number10
StatePublished - Oct 1 1995

Fingerprint

Pharmacokinetics
Glutathione Transferase
Lymphocytes
Flatulence
oltipraz
Hunger
Enzymes
Carcinogens
Fatigue
Glutathione
Headache

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Gupta, E., Olopade, O. I., Ratain, M. J., Mick, R., Baker, T. M., Berezin, F. K., ... Dolan, M. E. (1995). Pharmacokinetics and Pharmacodynamics of Oltipraz as a Chemopreventive Agent. Clinical Cancer Research, 1(10), 1133-1138.
Gupta, Elora ; Olopade, Olufunmilayo I. ; Ratain, Mark J. ; Mick, Rosemarie ; Baker, Theresa M. ; Berezin, Frances K. ; Benson III, Al B ; Dolan, M. Eileen. / Pharmacokinetics and Pharmacodynamics of Oltipraz as a Chemopreventive Agent. In: Clinical Cancer Research. 1995 ; Vol. 1, No. 10. pp. 1133-1138.
@article{263bc3eb749e42979fd12b0bb273403d,
title = "Pharmacokinetics and Pharmacodynamics of Oltipraz as a Chemopreventive Agent",
abstract = "Oral oltipraz, as a single-dose treatment, was evaluated as a chemopreventive agent in 31 normal subjects. In a subset of subjects, the relationship between plasma oltipraz concentrations and the induction of lymphocyte glutathione (GSH) and glutathione S-transferase (GST) enzyme levels was evaluated. Pharmacokinetic analysis revealed nonlinear disposition of oltipraz with disproportionate 40-fold increase and 9.5-fold decrease in peak plasma concentrations (Cmax) and p.o. clearance, respectively, over the dose range of 100-500 mg. There was no correlation between the oltipraz dose and the absorption rate or the time to reach Cmax. Since oltipraz undergoes extensive metabolism, saturable first-pass elimination could be one of the sources of nonlinearity. Pharmacodynamic evaluation was conducted based on the percentage of elevation of GSH and GST levels over baseline in lymphocytes of subjects receiving 100 mg and 125 mg oltipraz. Induction was observed in both dose groups with a time lag between the maximum concentrations of oltipraz and that of GSH or GST. We also observed a linear correlation between oltipraz Cmax and the corresponding GSH and GST elevations. Subjects with higher Cmax values showed a greater increase over baseline in the GSH and GST levels. Mild toxicities were observed at all dose levels. The most common were flatulence, hunger, fatigue, and headache. These preliminary results indicate that oltipraz may be effective in inducing GSH and GST, an enzyme capable of carcinogen elimination.",
author = "Elora Gupta and Olopade, {Olufunmilayo I.} and Ratain, {Mark J.} and Rosemarie Mick and Baker, {Theresa M.} and Berezin, {Frances K.} and {Benson III}, {Al B} and Dolan, {M. Eileen}",
year = "1995",
month = "10",
day = "1",
language = "English (US)",
volume = "1",
pages = "1133--1138",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

Gupta, E, Olopade, OI, Ratain, MJ, Mick, R, Baker, TM, Berezin, FK, Benson III, AB & Dolan, ME 1995, 'Pharmacokinetics and Pharmacodynamics of Oltipraz as a Chemopreventive Agent', Clinical Cancer Research, vol. 1, no. 10, pp. 1133-1138.

Pharmacokinetics and Pharmacodynamics of Oltipraz as a Chemopreventive Agent. / Gupta, Elora; Olopade, Olufunmilayo I.; Ratain, Mark J.; Mick, Rosemarie; Baker, Theresa M.; Berezin, Frances K.; Benson III, Al B; Dolan, M. Eileen.

In: Clinical Cancer Research, Vol. 1, No. 10, 01.10.1995, p. 1133-1138.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pharmacokinetics and Pharmacodynamics of Oltipraz as a Chemopreventive Agent

AU - Gupta, Elora

AU - Olopade, Olufunmilayo I.

AU - Ratain, Mark J.

AU - Mick, Rosemarie

AU - Baker, Theresa M.

AU - Berezin, Frances K.

AU - Benson III, Al B

AU - Dolan, M. Eileen

PY - 1995/10/1

Y1 - 1995/10/1

N2 - Oral oltipraz, as a single-dose treatment, was evaluated as a chemopreventive agent in 31 normal subjects. In a subset of subjects, the relationship between plasma oltipraz concentrations and the induction of lymphocyte glutathione (GSH) and glutathione S-transferase (GST) enzyme levels was evaluated. Pharmacokinetic analysis revealed nonlinear disposition of oltipraz with disproportionate 40-fold increase and 9.5-fold decrease in peak plasma concentrations (Cmax) and p.o. clearance, respectively, over the dose range of 100-500 mg. There was no correlation between the oltipraz dose and the absorption rate or the time to reach Cmax. Since oltipraz undergoes extensive metabolism, saturable first-pass elimination could be one of the sources of nonlinearity. Pharmacodynamic evaluation was conducted based on the percentage of elevation of GSH and GST levels over baseline in lymphocytes of subjects receiving 100 mg and 125 mg oltipraz. Induction was observed in both dose groups with a time lag between the maximum concentrations of oltipraz and that of GSH or GST. We also observed a linear correlation between oltipraz Cmax and the corresponding GSH and GST elevations. Subjects with higher Cmax values showed a greater increase over baseline in the GSH and GST levels. Mild toxicities were observed at all dose levels. The most common were flatulence, hunger, fatigue, and headache. These preliminary results indicate that oltipraz may be effective in inducing GSH and GST, an enzyme capable of carcinogen elimination.

AB - Oral oltipraz, as a single-dose treatment, was evaluated as a chemopreventive agent in 31 normal subjects. In a subset of subjects, the relationship between plasma oltipraz concentrations and the induction of lymphocyte glutathione (GSH) and glutathione S-transferase (GST) enzyme levels was evaluated. Pharmacokinetic analysis revealed nonlinear disposition of oltipraz with disproportionate 40-fold increase and 9.5-fold decrease in peak plasma concentrations (Cmax) and p.o. clearance, respectively, over the dose range of 100-500 mg. There was no correlation between the oltipraz dose and the absorption rate or the time to reach Cmax. Since oltipraz undergoes extensive metabolism, saturable first-pass elimination could be one of the sources of nonlinearity. Pharmacodynamic evaluation was conducted based on the percentage of elevation of GSH and GST levels over baseline in lymphocytes of subjects receiving 100 mg and 125 mg oltipraz. Induction was observed in both dose groups with a time lag between the maximum concentrations of oltipraz and that of GSH or GST. We also observed a linear correlation between oltipraz Cmax and the corresponding GSH and GST elevations. Subjects with higher Cmax values showed a greater increase over baseline in the GSH and GST levels. Mild toxicities were observed at all dose levels. The most common were flatulence, hunger, fatigue, and headache. These preliminary results indicate that oltipraz may be effective in inducing GSH and GST, an enzyme capable of carcinogen elimination.

UR - http://www.scopus.com/inward/record.url?scp=0028832190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028832190&partnerID=8YFLogxK

M3 - Article

C2 - 9815904

AN - SCOPUS:0028832190

VL - 1

SP - 1133

EP - 1138

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 10

ER -

Gupta E, Olopade OI, Ratain MJ, Mick R, Baker TM, Berezin FK et al. Pharmacokinetics and Pharmacodynamics of Oltipraz as a Chemopreventive Agent. Clinical Cancer Research. 1995 Oct 1;1(10):1133-1138.